EQ News and Press, Equillium Inc. From 03/22/24

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference, and the LD Mic...

2024-03-06 11:25:10 ET Over the past 3 months the biotech space is +30.4% and has only been outperformed by semiconductors, computer processing hardware and the computer peripherals industries. Additionally, the biotech sector is +13.6% in 2024, outdoing all of the major market aver...

2024-02-07 10:00:01 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Lilly, Zoetis, Abbott least shor...

A look at the top 10 most actives in the United States Palantir Technologies Inc. Class A (PLTR) rose 30.8% to $21.87 on volume of 421,271,485 shares InVivo Therapeutics Holdings Corp. (NVIV) rose 136.9% to $0.526 on volume of 188,439,590 shares New York Community Bancorp Inc. (NYCB) fell...

EQ101 Phase 2 study in alopecia areata is fully enrolled with topline data expected in Q2 2024 EQ302, an orally delivered multi-cytokine inhibitor of IL-15 & IL-21, will be advanced in place of further clinical development of EQ102 based on EQ302’s optimal delivery and increase...

EQ Bank Card launches in Québec as Carte Banque EQ Canada NewsWire Popular bank card gives customers the ability to earn, save, and spend their money TORONTO , Nov. 20, 2023 /CNW/ - EQ Bank (Banque EQ in Québec) is offering Québec customers...

Revenue Increases Over 24% Year Over Year - Adjusted EBITDA on Track to Profitability TORONTO, ON / ACCESSWIRE / November 16, 2023 / EQ Inc. (TSXV:EQ) ("EQ", "EQ Works" or the "Company"), a leader in AI and geospatial data driven software and solutions, announced its financial results today ...

Itolizumab continues to show clinically meaningful response in highly proteinuric subjects At Week 28, 73% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR) Itolizumab demonstrated a favorable safety and tolerability profile Equillium , ...

Equillium Inc. (EQ) is expected to report $-0.16 for Q3 2023

2023-11-08 17:32:06 ET More on Equillium Seeking Alpha’s Quant Rating on Equillium Historical earnings data for Equillium Financial information for Equillium For further details see: Equillium GAAP EPS of -$0.11 beats by $0.05, revenue of $8.87M be...